Highlights
- Piramal Pharma and RBL Bank recorded the sharpest FII stake declines in Q1 FY27, at -17.7 and -11.4 percentage points respectively.
- At least three of the five biggest declines trace to identifiable corporate events — a promoter capital infusion, a reported PE block-deal sale, and an anchor lock-in expiry — not open-market selling alone.
- DIIs have net bought roughly ₹4.16 lakh crore of Indian equities in CY2026 so far, against about ₹2.7 lakh crore of FII net selling over the same period.
- The ten stocks span banking, pharma, auto, gas utilities, railways, technology and metals — a spread that points to stock-specific triggers rather than one common theme.
Foreign institutional investors trimmed holdings across several Indian companies in the June 2026 quarter, even as domestic institutional investors continued to hold steady. FII ownership across major benchmark indices remains at the lower end of its 12-quarter range, making the latest round of Q1 FY27 shareholding disclosures a closely watched data point for institutional sentiment.
But a stock-by-stock read of the ten biggest FII decliners shows the picture is less about a broad foreign sell-off and more about a handful of one-off corporate actions that mechanically or deliberately moved the needle.
FII Stake Changes: Top 10 Decliners in Q1 FY27
| Stock | Q4 FY26 FII Holding | Q1 FY27 FII Holding | Change |
|---|---|---|---|
| Piramal Pharma | 30.2% | 12.5% | -17.7 pp |
| RBL Bank | 20.2% | 8.8% | -11.4 pp |
| Indraprastha Gas | 17.1% | 10.2% | -6.9 pp |
| Rail Vikas Nigam | 4.9% | 2.4% | -2.5 pp |
| Hyundai Motor India | 5.4% | 3.3% | -2.1 pp |
| Jain Resource Recycling | 3.0% | 1.2% | -1.8 pp |
| CE Info Systems | 3.2% | 1.5% | -1.7 pp |
| Pfizer | 2.8% | 1.7% | -1.1 pp |
| Blue Jet Healthcare | 0.9% | 0.4% | -0.5 pp |
| Gallantt Ispat | 0.1% | 0% | -0.1 pp |
Source: BSE/NSE quarterly shareholding filings
Why the Two Biggest Declines Happened
RBL Bank: The steepest single-stock swing in percentage-point terms wasn’t driven by FIIs selling in the open market. Emirates NBD Bank infused approximately $2.75 billion into RBL Bank via a preferential issue on June 18, 2026, taking a 60% stake and becoming the bank’s promoter for the first time.
Because promoter classification is a separate reporting category, the emergence of a new 60% promoter mechanically diluted every other shareholder class’s percentage, FII holding fell 11.4 percentage points to 8.8%, and mutual fund holding fell even more sharply, by over 22 percentage points, in the same quarter.
Existing institutional investors did not necessarily sell shares; their share of a now much-larger, differently structured capital base simply shrank. The amalgamation of ENBD’s India branches into RBL Bank is still pending final regulatory approvals, a development worth tracking for its own market impact.
Piramal Pharma: This was a genuine exit, not a dilution effect. Carlyle Group, which held an 18% stake in Piramal Pharma through its affiliate CA Alchemy Investments as of March 2025, had been reported to be planning a block-deal sale of up to 10% of the company, worth roughly ₹2,600-2,700 crore.
Carlyle’s FPI-classified holding falls under the FII bucket, and a stake reduction of this size lines up closely with the 17.7 percentage-point drop recorded for the June 2026 quarter. Separately, HDFC Mutual Fund also trimmed its own stake by about 2 percentage points in July 2026, though that shows up under domestic institutional holdings, not FII.
Hyundai Motor India: This decline coincides with a scheduled lock-in expiry rather than a shift in sentiment. Roughly 163 million shares, about 20% of Hyundai Motor India’s equity, largely held by pre-IPO and anchor investors, became eligible for sale from April 20, 2026, squarely within the June quarter.
Lock-in expiries typically release a wave of tradeable supply and often coincide with some institutional rebalancing, which is consistent with the stock’s FII holding easing to 3.3% from 5.4%.
The remaining names on the list, Indraprastha Gas, Rail Vikas Nigam, Jain Resource Recycling, CE Info Systems, Pfizer, Blue Jet Healthcare and Gallantt Ispat, saw comparatively smaller percentage-point declines, and no single identifiable corporate action was found in filings reviewed for this report; these may reflect more conventional portfolio rebalancing.
Sector Spread
The ten stocks span banking (RBL Bank), pharmaceuticals (Piramal Pharma, Pfizer, Blue Jet Healthcare), automobiles (Hyundai Motor India), city gas distribution (Indraprastha Gas), railways (Rail Vikas Nigam), technology (CE Info Systems) and metals/recycling (Jain Resource Recycling, Gallantt Ispat), a cross-sector spread that itself suggests stock-specific triggers rather than a single macro theme driving the quarter’s FII activity.
DIIs Cushion the Blow
Even as individual stocks saw sharp FII reductions, the broader market has leaned on domestic institutions this year. Domestic institutional investors have net bought roughly ₹4.16 lakh crore of Indian equities in calendar year 2026 through late June, against approximately ₹2.7 lakh crore of net FII selling over the same period. Mutual fund SIP inflows, a key pillar of that buying power, stood at ₹31,115 crore in April 2026, down marginally from March’s all-time high of ₹32,087 crore, but still 18% higher than April 2025’s ₹26,400 crore. That steady domestic flow is one reason broad indices have stayed comparatively resilient even as stock-specific FII exits like the ones above played out.
Track daily FII and DII activity on the NiftyTrader FII-DII Tracker: niftytrader.in/fii-dii-data
What to Watch in Q2 FY27
- Whether the September-quarter shareholding disclosures, due around mid-October 2026, show these declines were one-off events or the start of a broader trend.
- Progress on RBL Bank’s pending amalgamation of ENBD’s India branches, and any further clarity on Emirates NBD’s shareholding structure.
- Whether Carlyle proceeds with additional block-deal tranches in Piramal Pharma beyond what’s already reflected in the June quarter data.
NiftyTrader Desk View
| Parameter | Observation |
|---|---|
| Largest decline | Piramal Pharma (-17.7 pp), linked to Carlyle Group’s reported block-deal stake sale |
| Sharpest single-quarter dilution | RBL Bank (-11.4 pp), following Emirates NBD’s ₹26,015-crore promoter infusion |
| Event-driven vs sentiment-driven | At least 3 of the top 5 declines trace to identifiable corporate actions, not open-market selling alone |
| DII behaviour | DIIs have net bought ~₹4.16 lakh crore in CY2026 YTD versus ~₹2.7 lakh crore of FII net selling |
| Retail relevance | A single quarter’s shareholding change is not confirmation of a multi-quarter trend; subsequent quarters need tracking |
Source: NiftyTrader Desk, based on BSE/NSE shareholding filings, depository data and company disclosures
Read Next: Shiprocket IPO: Why This ₹1,617.5 Crore Issue Is Different from Recent Startup Listings
Disclaimer: This article is for informational purposes only and does not constitute investment advice. A reduction in FII shareholding does not by itself indicate a change in company fundamentals. Investors are advised to consult company filings and a registered financial advisor before making any investment decisions. Securities market investments are subject to market risks.
